– MSD will provide KEYTRUDA to be evaluated together with ABL Bio’s ABL103 in a Part 1b/2 medical trial
Beneath the phrases of the settlement, ABL Bio will conduct a section 1b/2 medical trial to judge the protection and efficacy of ABL103 together with KEYTRUDA. On this mixture examine, MSD will provide KEYTRUDA.
ABL103 is bispecific antibody that concurrently targets B7-H4 and 4-1BB. ABL103 is without doubt one of the pipeline packages through which ABL Bio’s 4-1BB based mostly bispecific antibody platform ‘Grabody-T’ has been utilized. Grabody-T is designed to activate T cells solely within the tumor microenvironment, decreasing the liver toxicity of typical 4-1BB monoclonal antibody and enhancing the antitumor exercise.
ABL103 additionally has mechanism to activate the 4-1BB signaling pathways within the tumor microenvironments the place the B7-H4 antigens exist, permitting T cells to selectively assault tumor cells whereas sparing regular cells. At present, the dose escalation a part of the section 1 medical trial for ABL103 is ongoing in
In the meantime, ABL Bio is growing varied medical and non-clinical belongings based mostly on its bispecific antibody platform ‘Grabody’. Greater than 15 medical initiatives for greater than 7 belongings, together with ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for various indications in varied nations, together with
KEYTRUDA ® is a registered trademark of Merck Sharp (OTC:) & Dohme LLC, a subsidiary of Merck & Co., Inc.,